American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions

被引:15
作者
Larenas-Linnemann, Desiree E. S. [1 ]
Hauswirth, David W. [2 ]
Calabria, Christopher W. [3 ]
Sher, Lawrence D. [4 ]
Rank, Matthew A. [5 ]
机构
[1] Hosp Med Sur, Mexico City, DF, Mexico
[2] Buckeye Allergy & Nationwide Childrens Hosp, Allergy & Dermatol Clin, Columbus, OH USA
[3] Dilley Allergy & Asthma, Helotes, TX USA
[4] Peninsula Res Associates, Rolling Hills Estates, CA USA
[5] Mayo Clin, Dept Otolaryngol Head & Neck Surg Audiol, Scottsdale, AZ USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; POLLEN IMMUNOTHERAPY; PRACTICE PATTERNS; FATAL REACTIONS; AUTOIMMUNE; CHILDREN; THERAPY; IGG;
D O I
10.2500/aap.2016.37.3981
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Little data in the literature exist concerning patients with certain underlying medical conditions who receive allergen subcutaneous immunotherapy (SCIT). Objective: To survey allergists' experience with SCIT in patients with medical conditions considered to impose an elevated risk for untoward outcomes. Methods: A Web-based survey was conducted among members of the American Academy of Allergy, Asthma & Immunology to query about their experience with SCIT in patients with certain medical conditions. Results: There were 1085 replies (21% response), of whom, 86% were U.S. based, 51% were suburban, 31% were academic, 42% were medium-sized practices, and 54% had > 15 years' experience. In responders' opinion, SCIT was "contraindicated" in patients with the following: acquired immune deficiency syndrome (AIDS) (48%), cancer (and still receiving active treatment) (33%), severe asthma (32%), and a history of transplantation (30%). Even so, survey responders collectively gave SCIT to > 2400 patients for each of these conditions: severe asthma, coronary artery disease, cancer in remission, and autoimmune disorders; and to >= 5400 patients with hypertension and >= 4100 women who became pregnant. The experience of colleagues with these patients rarely resulted in major problems (i.e., activation of underlying disease, systemic reactions to SCIT, or SCIT discontinuation), with the exception of severe asthma (12.5%), initiation of SCIT during pregnancy (5.4%), and AIDS (4.2%). For most other conditions, it was <= 1.5% (e.g., continue during pregnancy, cancer in remission, history of transplantation, positive human immunodeficiency virus and no AIDS). Conclusion: According to the experience of a large group of practicing allergists, the American Academy of Allergy, Asthma & Immunology members, few medical conditions seemed to pose an elevated risk for untoward outcomes from SCIT. Because these are survey results, prospective research might yield even more solid data.
引用
收藏
页码:E112 / E122
页数:11
相关论文
共 35 条
  • [1] Allergopharma, 2012, SPEC IMM IND CONTR I
  • [2] Standards for practical allergen-specific immunotherapy
    Alvarez-Cuesta, E.
    Bousquet, J.
    Canonica, G. W.
    Durham, S. R.
    Mailing, H. -J.
    Valovirta, E.
    [J]. ALLERGY, 2006, 61 : 1 - 20
  • [3] Evaluation of near-fatal reactions to allergen immunotherapy injections
    Amin, HS
    Liss, GM
    Bernstein, DI
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) : 169 - 175
  • [4] [Anonymous], 2007, J ALLERGY CLIN IMMUN, V119, P1012
  • [5] Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001
    Bernstein, DI
    Wanner, M
    Borish, L
    Liss, GM
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (06) : 1129 - 1136
  • [6] Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90
  • [7] 2006 American Academy of Allergy, Asthma & Immunology member immunotherapy practice patterns and concerns
    Coifman, Robert E.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (04) : 1012 - 1013
  • [8] Allergen immunotherapy: A practice parameter second update
    Cox, Linda
    Li, James T.
    Nelson, Harold
    Lockey, Richard
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (03) : S25 - S85
  • [9] Allergen immunotherapy: A practice parameter third update
    Cox, Linda
    Nelson, Harold
    Lockey, Richard
    Calabria, Christopher
    Chacko, Thomas
    Finegold, Ira
    Nelson, Michael
    Weber, Richard
    Bernstein, David I.
    Blessing-Moore, Joann
    Khan, David A.
    Lang, David M.
    Nicklas, Richard A.
    Oppenheimer, John
    Portnoy, Jay M.
    Randolph, Christopher
    Schuller, Diane E.
    Spector, Sheldon L.
    Tilles, Stephen
    Wallace, Dana
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (01) : S1 - S55
  • [10] Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy-treated mother
    Flicker, Sabine
    Marth, Katharina
    Kofler, Heinz
    Valenta, Rudolf
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (06) : 1358 - 1360